We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

100 hedge funds and large institutions have $1.27B invested in Theravance Biopharma in 2016 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 23 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 23

65% more capital invested

Capital invested by funds: $770M → $1.27B (+$503M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

2% more funds holding

Funds holding: 98 → 100 (+2)

72% less call options, than puts

Call options by funds: $272K | Put options by funds: $972K

Holders
100
Holders Change
+2
Holders Change %
+2.04%
% of All Funds
2.67%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
15
Increased
43
Reduced
23
Closed
12
Calls
$272K
Puts
$972K
Net Calls
-$700K
Net Calls Change
-$621K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$20.9M
2
WIM
Woodford Investment Management
United Kingdom
+$18.8M
3
Norges Bank
Norges Bank
Norway
+$11M
4
Northern Trust
Northern Trust
Illinois
+$7.65M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$6.23M

Top Sellers

1
O
OppenheimerFunds
New York
-$14.8M
2
SAM
Scion Asset Management
California
-$7.37M
3
RA
Royce & Associates
New York
-$4.09M
4
BIM
Bogle Investment Management
Massachusetts
-$3.06M
5
RSCM
Rock Springs Capital Management
Maryland
-$2.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
26
California Public Employees Retirement System
California
$3.4M +$245K +8,800 +10%
Invesco
27
Invesco
Georgia
$3.27M +$2.51M +90,152 New
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$2.87M +$619K +22,226 +39%
Marshall Wace
29
Marshall Wace
United Kingdom
$2.87M +$1.54M +55,362 +234%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$2.79M +$22.3K +800 +1%
TA
31
Teachers Advisors
New York
$2.12M – – –
AllianceBernstein
32
AllianceBernstein
Tennessee
$2.07M -$16.8K -604 -1%
PAMU
33
Pictet Asset Management (UK)
United Kingdom
$2.07M – – –
Swiss National Bank
34
Swiss National Bank
Switzerland
$2.02M +$52.9K +1,900 +4%
Boston Partners
35
Boston Partners
Massachusetts
$1.94M -$1.17M -42,046 -44%
NSEDCP
36
NJ State Employees Deferred Compensation Plan
New Jersey
$1.79M – – –
Deutsche Bank
37
Deutsche Bank
Germany
$1.74M +$9.16K +329 +0.7%
Allianz Asset Management
38
Allianz Asset Management
Germany
$1.69M +$1.29M +46,499 New
Ameriprise
39
Ameriprise
Minnesota
$1.68M +$1.29M +46,273 New
OWIM
40
Old West Investment Management
California
$1.65M +$71.6K +2,573 +6%
JP Morgan Chase
41
JP Morgan Chase
New York
$1.58M +$1.21M +43,391 +39,808%
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$1.56M – – –
EA
43
Emerald Acquisition
Washington
$1.53M -$106K -3,807 -8%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$1.38M +$292K +10,500 +38%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$1.33M +$71.6K +2,573 +8%
ProShare Advisors
46
ProShare Advisors
Maryland
$1.25M -$150K -5,388 -14%
BG
47
BlackRock Group
United Kingdom
$1.21M +$46.4K +1,665 +5%
CCM
48
Cupps Capital Management
Illinois
$1.2M +$924K +33,170 New
VEA
49
Virtus ETF Advisers
New York
$1.01M +$97.6K +3,506 +14%
Morgan Stanley
50
Morgan Stanley
New York
$987K -$154K -5,547 -17%
1
2
3 4 5

TBPH Hedge Fund Activity: Q3 2016 in Review

100 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2016, worth a combined $1.27B — up 65% from $770M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new TBPH positions and 12 closed out — a net gain of 3 holders — while 43 added to existing stakes and 23 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $20.9M. The largest seller was OppenheimerFunds, exiting entirely with an estimated $14.8M sold.

  • 100 institutional investors held Theravance Biopharma (TBPH) as of Q3 2016, up from 98 in Q2 2016.
  • Funds reported $1.27B of Theravance Biopharma stock for Q3 2016, up 65% quarter-over-quarter.
  • 15 funds opened new Theravance Biopharma positions in Q3 2016 and 12 closed out, a net change of +3 holders.
  • The largest Theravance Biopharma buyer in Q3 2016 was Fidelity Investments, an estimated $20.9M added.
  • The largest Theravance Biopharma seller in Q3 2016 was OppenheimerFunds, an estimated $14.8M sold.

Based on aggregated 13F filings for Q3 2016.